{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001352","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.914311+00:00","generated_at":"2026-05-25T01:54:08.151902+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aligos Q4 net loss $82.2M; cash $56.9M; ALG-000184 Phase 2 mid-2025","bullets":["Q4 net loss $82.2M ($13.08/share) vs $27.9M ($5.50) in Q4 2023; full-year net loss $131.2M vs $87.7M.","Cash & investments $56.9M at Dec 31, 2024; $105M private placement closed Feb 2025 extends runway into H2 2026.","Lead CAM-E candidate ALG-000184 Phase 2 expected to start mid-2025; 96-week data to be presented in 2025.","THR-β agonist ALG-055009 for MASH showed up to 46.2% placebo-adjusted median relative liver fat reduction at Week 12.","Lesley Ann Calhoun promoted to EVP, COO and CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001352","json":"https://secwatch.observer/filing/0001171843-25-001352.json","markdown":"https://secwatch.observer/filing/0001171843-25-001352.md","text":"https://secwatch.observer/filing/0001171843-25-001352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184325001352/0001171843-25-001352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184325001352/f8k_031025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:54:08.151902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}